読み込み中
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
終値時点
$84.11
−$0.30 · -0.36%
時間外
$84.11
$0.00 · 0.00%
10月9日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
日中レンジ
現在 $84.11
52週レンジ
現在 $84.11
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
88
大幅な割安
センチメント
66
強気
リスク
40
中程度のリスク
モメンタム
56
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
日中レンジ
現在 $84.11
52週レンジ
現在 $84.11
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 46.62億 USD | 40.33億 USD | 36.22億 USD | 29.1億 USD | 24.49億 USD |
| 売上原価 | 18.6億 USD | 15.95億 USD | 13.33億 USD | 10.27億 USD | 7.68億 USD |
| 粗利益 | 28.02億 USD | 24.38億 USD | 22.89億 USD | 18.83億 USD | 16.81億 USD |
| 研究開発 | 5.99億 USD | 5.52億 USD | 5.06億 USD | 4.84億 USD | 6.04億 USD |
| 販売・一般管理 | 12.91億 USD | 12.86億 USD | 11.85億 USD | 10.08億 USD | 8.11億 USD |
| 営業費用 | 18.9億 USD | 18.38億 USD | 16.91億 USD | 14.92億 USD | 14.15億 USD |
| 受取利息 | 1.13億 USD | 1.34億 USD | 1.35億 USD | 2380万 USD | 170万 USD |
| 支払利息 | 1830万 USD | 1900万 USD | 2030万 USD | 1860万 USD | 1880万 USD |
| 減価償却費と償却費 | 2.52億 USD | 2.18億 USD | 1.86億 USD | 1.56億 USD | 1.02億 USD |
| 営業利益 | 9.12億 USD | 6億 USD | 5.98億 USD | 3.91億 USD | 2.66億 USD |
| 純利益 | 8.36億 USD | 5.76億 USD | 5.42億 USD | 3.41億 USD | 2.17億 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$95.07
上昇余地（13.03%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2022年6月13日 | 4:1 | — | — |
発効済み 2022年6月13日
4:1
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P 500 ETF1557.T616.19億0.05%129.69兆 JPY0.09%￥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI11.17億0.05%2.3兆 USD0.03%$381.94+0.63%
Vanguard S&P 500 ETFVOO9.34億0.05%1.8兆 USD0.03%$715.59+0.61%
Vanguard Morningstar Mid-Cap ETFVO7.6億0.33%2264億 USD0.03%$81.14+0.92%
Invesco QQQ Trust, Series 1QQQ6.6億0.13%5069.24億 USD0.18%$751.27+0.49%
Vanguard Morningstar Growth ETFVUG4.47億0.12%3846億 USD0.03%$91.97+0.72%
iShares Core S&P 500 ETFIVV4.23億0.05%8972.05億 USD0.03%$781.97+0.60%
State Street SPDR S&P 500 ETFSPY3.89億0.05%8215.35億 USD0.09%$778.57+0.60%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Mid-Cap ETFVOInvesco QQQ Trust, Series 1QQQVanguard Morningstar Growth ETFVUGiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
